SYMBIOTECSymbiotec Pharmalab Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and dermatology. The company provides contract manufacturing (CMO) and contract development and manufacturing (CDMO) services, particularly for fermentation-based APIs, and operates large-scale manufacturing facilities with dedicated research and development and quality control laboratories. Its product portfolio includes APIs outside the cortico-steroids and hormone categories, with several products under development. The company serves clients in the pharmaceutical industry, including organizations involved in pharmaceutical manufacturing, contract manufacturing, and research and development, as well as global pharmaceutical companies. The company was founded in 2002 and is based in Indore, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SYMBIOTEC — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.62
- • RSI: 57
- • MACD: bullish
- • Price vs EMA21: above
- • 1-month return: +20.1%
- • 1-month vs NIFTY: +23.0% relative
Bull case
- • Debt/Equity: 0.62
- • RSI: 57
- • MACD: bullish
- • Price vs EMA21: above
Bear case
- • Valuation vs sector: P/E 71.8 vs sector 35.5
- • PEG ratio: 5.38
- • Volume: 0.6x 20-day average
- • Volume trend: 0.4x baseline
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Valuation vs sector: P/E 71.8 vs sector 35.5
- • PEG ratio: 5.38
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹75.70). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.